University of Washington

University of Washington was paid $36.65M by Medicaid between Jan 2018 and Dec 2024, across 195 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 72% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Washington

Rank by total paid#6 of 76

Median peer was paid$90K

This provider vs. median405×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	64,662	$1.25M
2019	67,761	$1.38M
2020	148,790	$6.81M
2021	411,732	$15.09M
2022	315,740	$9.11M
2023	106,892	$1.79M
2024incomplete	79,469	$1.23M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	72%	428,490	343,187	$26.38M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.6%	74,832	59,904	$1.32M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	3.3%	14,531	13,490	$1.23M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.1%	22,436	19,763	$771K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.1%	22,427	19,698	$762K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.3%	9,692	9,060	$468K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	15,850	15,554	$319K
84443	Thyroid stimulating hormone (TSH)	<1%	22,956	22,084	$300K
80050	General health panel	<1%	10,949	10,791	$299K
80061	Lipid panel	<1%	32,426	30,913	$299K
80053	Comprehensive metabolic panel	<1%	35,296	33,440	$281K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	3,152	2,980	$205K

183 more codes

87507		<1%	604	$180K
86235		<1%	1,852	$172K
86480		<1%	2,986	$167K
86780		<1%	12,442	$146K
86803		<1%	12,513	$137K
83013		<1%	2,191	$133K
82728		<1%	12,500	$129K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	19,270	$123K
82607		<1%	9,100	$112K
84403		<1%	4,847	$104K
86038		<1%	8,124	$90K
85027		<1%	16,371	$86K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	8,111	$85K
80048	Basic metabolic panel (calcium, ionized)	<1%	11,663	$78K
82746		<1%	6,411	$78K
87086	Culture, bacterial; quantitative colony count, urine	<1%	10,552	$75K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,886	$74K
83516		<1%	3,647	$66K
84270		<1%	3,376	$64K
87536		<1%	838	$62K
87529		<1%	985	$61K
82274		<1%	4,345	$59K
84466		<1%	5,679	$57K
87522	Neg quan hep c or qual rna	<1%	1,447	$55K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,113	$54K
82670		<1%	2,097	$53K
83036	Hemoglobin; glycosylated (A1C)	<1%	9,586	$52K
36415	Collection of venous blood by venipuncture	<1%	12,092	$45K
83655		<1%	3,828	$45K
86706		<1%	5,277	$44K
87340		<1%	4,831	$40K
84439		<1%	5,104	$38K
86481		<1%	459	$35K
83520		<1%	1,502	$34K
82043		<1%	6,801	$32K
86696		<1%	1,911	$31K
82570		<1%	7,317	$30K
87186		<1%	3,428	$29K
83540		<1%	5,714	$29K
86141		<1%	2,274	$29K
82542		<1%	1,505	$28K
84630		<1%	2,810	$26K
84702		<1%	2,052	$26K
83001		<1%	1,530	$26K
82525		<1%	2,413	$25K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	370	$23K
86695		<1%	1,915	$23K
87081		<1%	3,667	$23K
86225		<1%	2,029	$22K
84146		<1%	1,247	$22K
84153		<1%	1,704	$22K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	476	$22K
86787		<1%	1,930	$21K
87077		<1%	2,409	$21K
86200		<1%	1,687	$20K
87205		<1%	4,440	$18K
84590		<1%	1,849	$18K
82105		<1%	1,153	$18K
86769		<1%	611	$17K
84446		<1%	1,473	$17K
87631		<1%	141	$17K
83735		<1%	3,031	$17K
86762		<1%	1,255	$16K
81001		<1%	5,696	$15K
83690		<1%	2,405	$15K
87147		<1%	1,877	$15K
86364		<1%	1,373	$15K
87497		<1%	421	$14K
87070		<1%	1,764	$14K
80503		<1%	3,742	$14K
87088		<1%	1,852	$14K
80076		<1%	1,890	$14K
86140		<1%	3,116	$14K
83014		<1%	2,184	$13K
86258		<1%	1,215	$13K
83880		<1%	454	$13K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,265	$13K
85652		<1%	5,130	$13K
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	149	$12K
80504		<1%	1,377	$12K
86431		<1%	1,973	$10K
86704		<1%	1,057	$10K
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	<1%	25	$10K
83970		<1%	286	$9K
84165		<1%	1,682	$9K
87209		<1%	489	$9K
87806		<1%	1,848	$9K
84163		<1%	571	$8K
87102		<1%	1,064	$8K
83002		<1%	473	$8K
80502		<1%	384	$8K
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	65	$7K
84481		<1%	478	$7K
84202		<1%	510	$7K
80197		<1%	621	$6K
85610		<1%	1,880	$6K
86765		<1%	528	$6K
86708		<1%	629	$6K
87046		<1%	769	$6K
80500		<1%	972	$5K
86376		<1%	402	$5K
84550		<1%	1,380	$5K
84480		<1%	354	$5K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	84,323	$5K
83525		<1%	411	$5K
86160		<1%	201	$4K
86735		<1%	371	$4K
87177		<1%	507	$4K
82248		<1%	1,131	$4K
0097U		<1%	347	$4K
87338		<1%	296	$4K
86800		<1%	239	$4K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	14	$3K
86850		<1%	384	$3K
82677		<1%	112	$3K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	206	$3K
86334		<1%	362	$3K
92060		<1%	39	$3K
87593		<1%	18	$3K
83993		<1%	147	$3K
83521		<1%	110	$2K
87799		<1%	173	$2K
86256		<1%	97	$2K
87210		<1%	414	$2K
87252		<1%	55	$2K
85730		<1%	504	$2K
86255		<1%	145	$2K
87999		<1%	52	$2K
84460		<1%	390	$2K
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	<1%	26	$2K
86003		<1%	30	$2K
87075		<1%	181	$2K
87530		<1%	26	$2K
86336		<1%	114	$2K
87481		<1%	106	$2K
82150		<1%	244	$1K
82947		<1%	410	$1K
84100		<1%	323	$1K
86147		<1%	14	$1K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	15	$1K
80178		<1%	164	$1K
86900		<1%	387	$947.98
82550		<1%	178	$947.74
86901		<1%	358	$897.04
82977		<1%	130	$793.17
82627		<1%	41	$784.75
86146		<1%	14	$750.42
82365		<1%	92	$737.48
86665		<1%	24	$736.02
99072		<1%	74,208	$610.30
92015	Determination of refractive state	<1%	93	$590.04
82950		<1%	134	$561.98
83498		<1%	26	$547.51
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	17	$547.34
83010		<1%	42	$545.69
84425		<1%	28	$542.70
87184		<1%	97	$522.74
82103		<1%	42	$479.50
86592		<1%	139	$471.40
82247		<1%	88	$406.06
87106		<1%	39	$384.21
85245		<1%	15	$348.16
84156		<1%	116	$319.23
86664		<1%	24	$310.07
86036		<1%	30	$302.08
86381		<1%	12	$265.68
85046		<1%	57	$246.32
85246		<1%	14	$224.04
85384		<1%	25	$223.84
82172		<1%	14	$219.17
83883		<1%	13	$185.42
83020		<1%	20	$180.45
84450		<1%	37	$176.99
86015		<1%	15	$150.10
85379		<1%	13	$133.92
85060		<1%	13	$128.77
82565		<1%	27	$120.99
80069		<1%	13	$80.58
85670		<1%	12	$78.52
85390		<1%	12	$70.44
86308		<1%	13	$67.55
86593		<1%	13	$47.08
81511		0%	502	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCOLLANTES, MARCELO (CHIEF FINANCIAL OFFICER LABMED)